{"id":"full-boosted-fosamprenavir","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Nausea"},{"rate":"8-12","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"5-8","effect":"Vomiting"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"10-20","effect":"Lipid abnormalities"}]},"_chembl":{"chemblId":"CHEMBL1664","moleculeType":"Small molecule","molecularWeight":"585.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosamprenavir is a prodrug that is converted to amprenavir in vivo. It inhibits HIV protease, an enzyme essential for processing viral polyproteins into functional components. When combined with ritonavir (a pharmacokinetic booster), ritonavir inhibits cytochrome P450 metabolism, increasing fosamprenavir plasma concentrations and allowing for improved dosing convenience and efficacy.","oneSentence":"Fosamprenavir is a protease inhibitor that, when boosted with ritonavir, blocks HIV protease to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:31.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT00363142","phase":"PHASE3","title":"A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"HIV Infection, Infection, Human Immunodeficiency Virus","enrollment":211}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fosamprenavir","ritonavir"],"phase":"phase_3","status":"active","brandName":"Full Boosted Fosamprenavir","genericName":"Full Boosted Fosamprenavir","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosamprenavir is a protease inhibitor that, when boosted with ritonavir, blocks HIV protease to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}